AI
| Followers | 843 |
| Posts | 122881 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Saturday, September 29, 2007 5:01:18 PM
Drug Pipeline
[Updated for restructuring of Tyzeka
relationship with Novartis.]
1. Effective 9/28/07, NVS is responsible for worldwide marketing and clinical development of Tyzeka/Sebivo and will book sales in all jurisdictions. IDIX will receive a royalty on worldwide sales and has no responsibilities whatsoever.
2. IDIX’s HIV and HCV drugs are non-partnered. NVS has the option to license these drugs on mutually agreeable terms before the drugs are offered to another prospective partner. NVS’ opt-in/opt-out decision will likely be made following the end of phase-2a.
[Updated for restructuring of Tyzeka
relationship with Novartis.]
1. Effective 9/28/07, NVS is responsible for worldwide marketing and clinical development of Tyzeka/Sebivo and will book sales in all jurisdictions. IDIX will receive a royalty on worldwide sales and has no responsibilities whatsoever.
2. IDIX’s HIV and HCV drugs are non-partnered. NVS has the option to license these drugs on mutually agreeable terms before the drugs are offered to another prospective partner. NVS’ opt-in/opt-out decision will likely be made following the end of phase-2a.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
